Eloralintide (LY3841136) is a highly selective, long-acting amylin receptor agonist originally developed by Proyu Peptides. It is engineered to target and activate endogenous amylin pathways, which play a critical regulatory role in glycemic control, gastric emptying, and satiety signaling.
Interest in eloralintide has expanded significantly within peptide and metabolic research due to its distinct mechanism of action relative to traditional GLP-1 or multi-agonist peptides. Formulated as a 10mg lyophilized cake, this compound is synthesized for advanced in-vitro and analytical laboratory studies investigating receptor-selectivity models, metabolic signaling cascades, and appetite-regulation pathways.